Originalarbeiten in Zeitschriften
Werbung
Originalni radovi u časopisima R. P. Baum (1985-2013) 1. Baum RP, Happ J, Maul FD, Standke R, Hör G: 99mTcO4-Uptake und TSH-RezeptorAutoantikörper. Vergleichende Untersuchung bei M. Basedow und anderen Schilddrüsenerkrankungen. Nucl Med 24 (1985) 141-145 2. Maul FD, Hör G, Standke R, Kober G, Klepzig jr H, Dörr G, Baum RP, Happ J, Kaltenbach M: Anforderungen an die ergometrische Myokardszintigraphie mit Thallium-201 vor und nach Koronarrevaskularisation am Beispiel der transluminalen Angioplastik. Nuklearmediziner 8 (1985) 251-263 3. Baum RP, Maul FD, Klapdor R, Senekowitsch R, Lorenz M, Hottenrott C, Montz R, Happ J, Kriegel H, Chatal JF, Hör G: Immunszintigraphie kolorektaler Karzinome mit J-131markierten monoklonalen Antikörpern (19-9/Anti-CEA). Erste Ergebnisse. Nuc Compact 16 (1985) 121-128 4. Klepzig jr H, Standke R, Baum R, Maul FD, Hör G, Kaltenbach M: Verlaufsbeobachtungen bei chronischer Aorteninsuffizienz. Z Kardiol 74 (1985) 348-352 5. Senekowitsch R, Baum RP, Maul FD, Wenisch HJC, Möllenstädt S, Kriegel H, Hör G: Biokinetische Studien zur szintigraphischen Darstellung xenotransplantierter menschlicher Pankreaskarzinome mit Jod-131-markierten F(ab')2 -Fragmenten verschiedener monoklonaler Antikörper. Nuc Compact 16 (1985) 414-419 6. Meyer T, Grützmacher P, Bussmann WD, Baum RP, Krzymanek HJ, Faßbinder W: Transluminale Angioplastie zur Behandlung von Verschlüssen der Nierenarterien. Angio Arch 10 (1985) 29 7. Maul FD, Wenisch HJC, Schumm-Draeger PM, Bittner G, Wanner U, Standke R, Senekowitsch R, Gerspach H, Baum RP, Hör G: Nachsorge des Schilddrüsenkarzinoms: Stellung der Thallium-201 Szintigraphie. Nuklearmediziner 9, (1986): 125-134 8. Klepzig jr H, Skupin M, Standke R, Baum R, Kunkel B, Hör G, Satter P, Kaltenbach M: Chronic aortic regurgitation: Dependence of postoperative course from preoperative left ventricular enddiastolic volume and regurgitated blood volume. Z Kardiol 75, Suppl 2 (1986) 120-123 9. Klepzig jr H, Reifart N, Baum R, Skupin M, Standke R, Satter P, Hör G, Kaltenbach M: Persistierende Volumenbelastung des linken Ventrikels nach chirurgischer Korrektur einer chronischen Aorteninsuffizienz. Z Kardiol 75 (1986) 170-175 10. Baum RP, Hör G: Gammakamera-Funktionsszintigraphie in der Differentialdiagnose des M. Basedow: Ergebnisse bei 423 Patienten. Röntgenpraxis 39 (1986): 425-428 11. Lorenz M, Happ J, Hottenrott C, Maul FD, Baum RP, Hör G, Encke A: Klinische Überprüfung des Tumormarkers CA 19-9 im Vergleich zum carcinoembryonalen Antigen (CEA) in der chirurgischen prä-und postoperativen Diagnostik. Nucl Med 25 (1986) 9-14 12. Klepzig jr H, Mildenberger D, Baum RP, Jungmann E, Standke R, Siede WH, Maul FD, Hör G, Kaltenbach M: Wirkung von Captopril bei chronischer Aorteninsuffizienz. Z Kardiol 75 (1986) 283-290 13. Hör G, Standke R, Klepzig jr H, Maul FD, Tüngerthal S, Tezak S, Reifarth N, Kanemoto N, Happ J, Baum RP: Äquilibrium-Radionuklid-Ventrikulographie: Vergleich mit Echokardiographie und digitaler Subtraktionsangiokardiographie; Multi-Parameterbewertung. Nuklearmediziner 9 (1986) 211-234 14. Lorenz M, Herrmann G, Baum RP, Schulz M, Hör G, Hottenrott C, Encke A: Vergleichende Immunhistochemie und Korrelation zu Serumspiegeln von CA 19-9 und CEA bei gastrointestinalen Tumoren. Nuc Compact 18 (1987) 102-108 Originalni radovi u časopisima R. P. Baum (1985-2013) 15. Lorenz M, Hottenrott C, Baum RP, Maul FD, Kirkowa-Reimann M, Hör G, Encke A: CA 19-9 and CEA in the differential diagnosis of isolated liver metastases compared to clinical laboratory tests. Nucl Med Commun 8 (1987) 787-796 16. Baum RP, Lorenz M, Senekowitsch R, Albrecht M, Hör G: Klinische Ergebnisse der Immunszintigraphie und Radioimmuntherapie. Nucl Med 26 (1987) 68-78 17. Baum RP, Lorenz M, Hör G: Radioimmunszintigraphie bei kolorektalen Karzinomen Stellenwert in der Rezidivdiagnostik nach 2 Jahren klinischer Erfahrung. Nuklearmediziner 10 (1987) 219-234 18. Schwabe D, Sahm St, Gerein V, Happ J, Kropp-v.Rabenau H, Maul F, Baum RP, Manegold K, Nitz C, Hör G, Kornhuber B: 131-metaiodobenzylguanedine therapy of neuroblastoma in childhood. One year of therapeutic experience. Eur J Pediatr 146 (1987) 246-250 19. Happ J, Baum RP, Frohn J, Weimer B, Halbsguth A, Lochner B. Brandhorst I, Hör G: Immunszintigraphie mit In-111-DTPA-markierten monoklonalen Antikörpern: Vergleich zwischen ECT und planarer Szintigraphie. Nucl Med 26 (1987) 258-263 20. Hör G, Baum RP: Fortschritte der Immunszintigraphie und Probleme von Heilversuchen mit radioaktiv markierten monoklonalen Antikörpern (Frankfurter Erfahrungen). Nuklearmediziner 10 (1987) 267-278 21. Hör G, Kober G, Maul FD, Klepzig H jr, Standke R, Bittner G, Kanemoto N, Happ J, Baum RP: Nuclear cardiology results before and after percutaneous transluminal angioplasty (PTCA): 1978-1986. Nucl Med Commun 8 (1987) 127-137 22. Klepzig jr H, Standke R, Baum RP, Tezak S, Mildenberger D, Maul FD, Hör G, Kaltenbach M: Vergleich von Belastungs-EKG und Radionuklidventrikulographie bezüglich Nachweis einer Myokardischämie bei isolierten Stenosen des Ramus interventricularis anterior. Nucl Med 27 (1988) 57-62 23. Busse E, Baum RP, Kornhuber B, Hör G: Untersuchungen über die J-131-MIBGSpeicherkapazität von verschiedenen humanen und murinen Neuroblastomzell-Linien. Nuc Compact 19 (1988) 2-6 24. Encke A, Baum RP, Hottenrott C, Lorenz M, Hör G: Die Bedeutung der Immunszintigraphie für Metastasen- und Rezidivchirurgie. Chirurg 59 (1988) 309-316 25. Busse E, Baum RP, Hör G, Kornhuber B: Nachweis der Bindung von J-131-Meta-JodBenzylguanidin an Strukturen der Plasmamembran von Neuroblastomzell-Linien. Nucl Med 27 (1988) 95-97 26. Grützmacher P, Scheuermann E, Löw I, Bergmann M, Rauber K, Baum R, Heuser J, Schoeppe W: Correction of renal anemia by recombinant human erythropoietin: effects on myocardial function. Contrib Nephrol 66 (1988) 176-184 27. Grützmacher P, Bussmann WD, Meyer TH, Starck E, Kollath J, Baum RP, Fassbinder W, Schoeppe W: Non-operative revascularisation of renal artery occlusion by transluminal angioplasty. Nephrol Dial Transplant 2 (1988) 130-137 28. Baum RP, Grützmacher P, Rauber K, Meyer Th, Schuttenbach M von, Standke R, Kollath J, Hör G: Vergleich von computerisierter Nierensequenzszintigraphie und digitaler Subtraktionsangiographie vor und nach perkutaner transluminaler Angioplastie von Nierenarterienstenosen. Therapiewoche 38 (1988): 2470-2477 Originalni radovi u časopisima R. P. Baum (1985-2013) 29. Baum RP, Lorenz M, Hottenrott C, Albrecht M, Senekowitsch R, Happ J, Hertel A, Spitz J, Hör G: Radioimmunoscintigraphy using monoclonal antibodies to CEA, CA 19-9, and CA 125. Int J Biol Markers 3 (1988) 177-184 30. Hör G, Brandhorst I, Staczewski S, Maul FD, Holzmann H, Baum RP: AIDS und Nuklearmedizin (Frankfurter Erfahrungen und derzeitiger Stand). Nuklearmediziner 11 (1988) 287-298 31. Baum RP, Hertel A, Hör G: Immunszintigraphische Diagnostik in der Nachsorge gynäkologischer Tumoren. Gynäkologe 22 (1989) 33-38 32. Baum RP, Hernaiz-Driever P, Drahovsky D, Hör G: A rapid method for the determination of human CEA/mouse anti-CEA immune complexes in patients undergoing immunoscintigraphy. Eur J Nucl Med 15 (1989) 321-325 33. Baum RP, Hertel A, Lorenz M, Schwarz A, Encke A, Hör G: Tc-99m-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results. Nucl Med Commun 10 (1989) 345-352 34. Hör G, Baum RP: Blutungsquellennachweis: Stand nuklearmedizinischer Diagnostik. Med Welt 40 (1989) 241-246 35. Baum RP, Klepzig jr H, Hertel A, Hör G: Nachweis, Größenbestimmung und Differentialdiagnostik des akuten Myokardinfarktes mit Indium-111-markierten monoklonalen Antikörpern. Nuklearmediziner 12 (1989) 121-132 36. Baum RP, Klepzig jr, H, Hertel A, Hör G: Detection, sizing and differential diagnosis of acute myocardial infarction with Indium-111 labelled monoclonal antimyosin antibodies. Nuklearmediziner 12, No. 2 (1989) 121-132 37. Hör G, Bittner G, Standke R, Maul FD, Klepzig H jr, Baum RP: Tc-99m-Isonitril ("MIBI"): Chancen zur Verbesserung der Myokardszintigraphie oder Ersatz für 201Tl? (Erste Frankfurter Erfahrungen mit Literaturresumé). Nuklearmediziner 12 (1989) 133-146 38. Schäfer D, Pfuhl JP, Baum R, Rößler M, Baumann R: Cytogenetische, endokrinologische sowie immunologische Studien an kultiviertem Gewebe ektoper Schwangerschaften. Zentrlbl f Gynäkol 111 (1989) 1476-1485 39. Baum RP, Hertel A, Hör G: Immunszintigraphie mit radionuklidmarkierten monoklonalen Antikörpern zur Tumordiagnostik und bei benignen Erkrankungen. Immun Infekt 17 (1989) 22-24 40. Lorenz M, Baum RP, Oremek G, Inglis R, Reimann-Kirkowa M, Hör G, Seiffert U, Hottenrott C: Tumor markers, liver function tests and symptoms in 115 patients with isolated colorectal liver metastases. Int J Biol Markers 4 (1989) 18-26 41. Baum RP, Lorenz M, Hertel A, Baew-Christow T, Schwarz A, Hör G: Erfolgreiche immunszintigraphische Tumordetektion mit Technetium-99m markierten monoklonalen Anti-CEA-Antikörpern. Onkologie 12 (1989) 26-29 42. Baum RP, Saccavini JC, Buhl R, Schuttenbach von M, Berthold F, Lorenz M, Happ J, Manegold K, Senekowitsch R, Douillard JY, Hör G: Radioimmunotherapy using 131iodine-labelled monoclonal antibodies: Initial clinical experience and critial evaluation. Rev Esp Med Nuclear 8 (1989) 18-26 43. Frohn J, Baum RP, Happ J, Weimer B, Halbsguth A, Lochner , Hör G: Intraindividual comparison of SPECT and planar immunoscintigraphy with 111-In-DTPA labeled anti- Originalni radovi u časopisima R. P. Baum (1985-2013) CEA F(ab')2 monoclonal antibody fragments (BW 431/31). Nuc Compact 20 (1989) 161165 44. Boeckmann W, Baum RP, Schuldes H, Kramer W, Hertel A, Baew-Christow T, Hanke P, Jonas D: Tumorimaging of bladder carcinoma and metastases with radiolabelled monoclonal anti-CEA antibodies. Br J Cancer 62 (1990) 81-84 45. Busse E, Baum RP, Rohrbach E, Hör G, Kornhuber B: In vitro und in vivo Wirkung von Schilddrüsenhormon auf das Wachstum von Neuroblastomzellen. I. Effekt von Trijodthyronin in vitro. Nucl Med 29 (1990) 120-124 46. Busse E, Baum RP, Hör G, Kornhuber B: In vitro und in vivo Wirkung von Schilddrüsenhormon auf das Wachstum von Neuroblastomzellen. II. Effekt von Thyroxin in vivo. Nucl Med 29 (1990) 125-128 47. Chetanneau A, Baum RP, Lehur PA, Liehn JC, Perkins AC, Bares R, Bourguet P, Herry JY, Saccavini JC, Chatal JF: Multi-centre immunoscintigraphic study using indium-111labelled CEA-specific and/or 19-9 monoclonal antibody F(ab')2 fragments. Eur J Nucl Med 17 (1990) 223-229 48. Grützmacher P, Bergmann M, Löw J, Rauber K, Baum RP, Schoeppe W: Cardiale Veränderungen unter Langzeittherapie der renalen Anämie mit rekombinantem Erythropoietin. Nieren- und Hochdruckkrankheiten 19 (1990) 192-198 49. Hartmann A, Frenkel J, Hopf R, Baum R, Hör G, Schneider M, Kaltenbach M: Kardiale Befunde bei Patienten mit Amyloidose: Wie sicher läßt sich klinisch die Diagnose stellen? Herz/Kreisl 22 (1990) 281-285 50. Hartmann A, Frenkel J, Hopf R, Baum RP, Hör G, Schneider M, Kaltenbach M: Is technetium-99m-pyrophosphate scintigraphy valuable in the diagnosis of cardiac amyloidosis? Int J Cardiac Imaging 5 (1990) 227-231 51. Hertel A, Baum RP, Auerbach B, Herrmann A, Hör G: Klinische Relevanz humaner AntiMaus-Antikörper (HAMA) in der Immunszintigraphie. Nucl Med 29 (1990) 221-227 52. Hertel A, Baum RP, Lorenz M, Baew-Christow T, Encke A, Hör G: Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow up of colorectal cancer and other tumours producing CEA. Br J Cancer 62 (1990) 34-36 53. Spitz J, Dziuk H, Köllermann NW, Baum RP: Die klinische Relevanz der tumorassoziierten Antigene PAP und PSA für die Diagnostik und Verlaufskontrolle des Prostatakarzinoms. Tumordiagn Ther 11 (1990) 51-59 54. Qizhong Mo, Baum RP, Hertel A, Hör G: Comparison of various correlation on IRMA for CA 19-9 and CA50 in the digestive system tumor. Nucl Science Techn 1 (1990) 234-238 55. Qizhong Mo, Baum RP, Hertel A, Hör G, Schnorr G: Determination of clinical significance of CA 50 in the serum of cancer patients. Chin J Nucl Med 11 (1991) 120-121 56. Baum RP, Hör G: Wertigkeit nuklearmedizinischer Methoden in der HepatoGastroenterologie - Tumornachweis. Z Gastroenterologie, Verh Bd 26 (1991) 134-136 57. Juweid M, Fischman AJ, Rubin RH, Baum RP, Strauss HW: Comparison between Tc99m-labelled monoclonal anti-granulocyte antibody and In-111-labelled IgG for the detection of focal sites of infection in rats. Nucl Med Commun 12 (1991) 637-644 58. Saal W, Happ J, Cordes U, Baum RP, Schmidt M: Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism. Fertil Steril 56 (1991) 319-324 Originalni radovi u časopisima R. P. Baum (1985-2013) 59. Baum RP, Maul FD, Hör G: Wertigkeit der Nierenszintigraphie unter ACE-Blockade ("Captopril-Szintigraphie") in der Diagnostik der renovaskulären Hypertonie. Nuklearmediziner 14 (1991) 227-240 60. Maul FD, Baum RP, Hör G, Standke R: Nierenfunktions-Szintigraphie und Clearance zur Erfolgsbeurteilung einer transluminalen Angioplastie bei Nierenarterienstenosen. Nuklearmediziner 14 (1991) 241-248 61. Hartmann A, Baum RP, Klepzig jr H, Huth A, Mondorf U, Herrmann G, Cieslinksi G, Olbrich HG, Hör G, Krause E, Kaltenbach M, Kober G: Erfahrungen mit dem Einsatz der monoklonalen Indium-111 Antimyosin-Szintigraphie in der Diagnostik von Abstoßungsepisoden nach orthotoper Herztransplantation. Z Kardiol 80 (1991) 454-458 62. Kramer W, Boeckmann W, Schuldes H Baum RP: Anti-CEA-Immunszintigraphie beim infiltrierenden Harnblasenkarzinom. NBP 16 (1991) 122-126 63. Hör G, Maul FD, Kornhuber B, Schwabe D, Hesse J, Manegold KH, Baum RP, V. Gerein: Outcome of I-131-metaiodobenzylguanidine therapy of neuroblastoma: seven years after. J Nucl Biol Med 35 (1991) 207-215 64. Fommei E, Mezzasalma L, Ghione S, Volterrani D, Oei Y, Hilson AJW, Carrieri M and The European Captopril Radionuclide Test Multercenter Study Group: European Captopril Radionuclide Test Multicenter Study. Preliminary Results. Inspective Renographic Analysis. AJH 4 (1991) 690S-697S 65. Attard AR, Thomas GD, Chappell MJ, Taylor DN, Baum RP, Dykes PW, Godfrey KR, Fraser IA, Bradwell AR: High dose high affinity antibody and dexamethasone increase antibody uptake by colorectal cancer. Antibody Immunoconj and Radiopharm 4 (1991) 871876 66. Gonzalez P, Escobar MI, Csendes A, Lillo G, Fordor M, Guzman G, Baum RP, Massardo T, Gainza V, Otarola S, Zavalar A: Immunocintigrafia en cancer gastrico con anticuerpo monoclonal anti-CEA BW 431/26 marcado con Tc-99m. - Gastric cancer: Immunoscintigraphy with Tc-99m labeled anti-CEA BW 431/26 monoclonal antibody. Rev. Med. Chile 119 (1991) 572-576 67. Fischer P, Baum RP, Tauber M, Boeckmann W, Weier S, Scherberich JE: Immunoscintigraphic localization of renal tumors in an extracorporal perfusion model with a monoclonal antibody against gamma-glutamyltransferase. Cancer Immunol Immunother 35 (1992) 283-288 68. Hertel A, Baum RP, Baew-Christow T, Hör G: Thrombosediagnostik mit einem murinen Anti-Thrombozyten-Antikörper (Tc-99m-B4): Erste klinische Erfahrungen. Nucl. Med. 32 (1993) 178-182 69. Hertel A, Baum RP: Influence of human anti-murine antibodies on in-vitro assays in ovarian cancer patients. Hybridoma 12 (1993) 571-576 70. Baum RP, Noujaim AA, Nanci I, Moebus V, Hertel A, Niesen A, Donnerstag B, Sykes T, Boniface G, Hör G: Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 12 (1993) 583-589 71. Fommei E, Ghione S, Hilson AJW, Mezzasalma L, Oei HY, Piepsz A, Volterrani D and the European Multicentre Study Group: Captopril radionuclide test in renovascular hypertension: a European multicentre study. Eur J Nucl Med 20 (1993) 617-623 Originalni radovi u časopisima R. P. Baum (1985-2013) 72. Baum RP, Adams S, Knecht R, Hertel A, Howaldt HP, Kiefer J, Niesen A, Adamietz IA, Noujaim AA, Boniface GR, Sykes T, Hör G: A novel Tc-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECT. Acta Oncologica 32 (1993) 747-751 73. Donnerstag B, Oltrogge JB, Henzel K, Rüenauver A, Baum RP: Functional analysis of peripheral blood lymphocytes from healthy volunteers. J Clin Lab Immunol 40 (1993) 91-95 74. Baum RP, Niesen MD, Hertel A, Nancy A, Hess H, Donnerstag B, Sykes TR, Sykes J, Suresh MR, Noujaim AA, Hör G: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian cancer. Cancer 73 (1994) 1121-1125 75. Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff G, Goldenberg M, Hör G: Inital clinical results with Tc-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 73 (1994) 896-899 76. Donnerstag B, Baum RP, Oltrogge JB, Hertel A, Hör G: A preliminary study on the functional analysis of peripheral blood lymphocytes from ovarian cancer patients developing HAMA after immunoscintigraphy. Int J Biol Markers 9 (1994) 115-120 77. Brümmendorf TH, Kaul S, Schuhmacher J, Baum RP, Matys R, Klivenyi G, Adams S, Bastert G: Immunoscintigraphy of human mammary carcinoma xenografts using monoclonal antibodies 12H12 and BM-2 labeled with Tc-99m and radioiodine. Cancer Res 54 (1994) 4162-4168 78. McQuarrie SA, Baum RP, Golberg L, Niesen A, Golberg K, Noujaim AA, McEwan AJB: A pharmacokinetic comparison of murine and chimeric forms of the 99mTc labelled 174H.64 monoclonal antibody.J Nucl Biol Med 38 (1994) 140-144 79. Kiefer J, Baum RP, Knecht R. Hertel A, Niesen A, v. Ilberg Ch, Hör G: Immunszintigraphie von Karzinomen im Kopf-Hals-Bereich mit dem Technetium-99m markierten monoklonalen Antikörper 174H.64: Ein neues diagnostische Verfahren. Z HNO 42 (1994) 546-552 80. Helm G, Klein C, Baum RP, Niesen A, Frenz M, Howaldt HP: Immunszintigraphie als Methode zum Staging von Mundhöhlenkarzinomen. Dtsch Z Mund Kiefer GesichtsChir 18 (1994) 289-293 81. Rachel U, Baum RP, Fischer P, Jonas D, Scherberich JE: Monoclonal antibody 138H11 in immunoscintigraphy of human kidney tumors - In vitro results. Investig Urol Berl 5 (1994) 66-68 82. Oriuchi N, Endo K, Watanabe N, Sugiyama S, Asao T, Takenoshita S, Nagamachi Y, Baum RP: Semiquantitative SPECT tumor uptake of Tc-99m-labeled anti-CEA monoclonal antibody in colorectal tumor. J Nucl Med 36 (1995) 679-683 83. Donnerstag B, Oltrogge JB, Baum RP, Skierlo M, Niesen A, Hör G, Träger L: Immunological profile of patients with ovarian cancer under immunostimulation with murine monoclonal antibodies. Int J Oncol 6 (1995) 853-858 84. Adamietz IA, Schemmann F, Baum RP, Knecht R, Saran F, Mose S, Thilmann C, Hör G, Böttcher HD: Wertigkeit der SPECT-Immunszintigraphie für die Bestrahlungsplanung bei Patienten mit Plattenepithelkarzinomen im HNO-Bereich. Strahlenther Onkol 171 (1995) 278-283 85. Krause BJ, Gürtner C, Kranert WT, Maul FD, Baum RP, Hör G: Validation of a dualisotope technique using 123-I-MIBG and 201-Tl in the assessment of sympathetic rein- Originalni radovi u časopisima R. P. Baum (1985-2013) nervation following heart transplantation: Phantom and patient studies. Nucl Med Commun 16 (1995) 675-682 86. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hör G, Noujaim AA: Antiidiotype induction therapy: Evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA 125 murine monoclonal antibody B43.13. Hybridoma 14 (1995) 199-203 87. Donnerstag B, Baum RP, Oltrogge J, Henzel K, Träger L, Hör G: Evaluation of tumor immunity in patients with ovarian cancer after immunoscintigraphy in a long-term follow-up. Hybridoma 14 (1995) 191-199 88. Adams S, Hovy L, Baum RP, Adams M, Maul FD, Kahla-Witzsch H, Zichner L, Jonas D, Hör G: Intraoperative Metastasenlokalisation mit einer handgeführten Gammasonde. Nucl Med 34 (1995) 161-164 89. Sykes TR, Woo TK, Baum RP, Qi P, Noujaim AA: Direct labeling of monoclonal antibodies with Technetium-99m by photoactivation. J Nucl Med 36 (1995) 1913-1922 90. Steinsträßer A, Oberhausen E and the European Multicenter Trial Group: Anti-CEA Labelling Kit BW 431/26. Nucl Med 34 (1995) 232-242 91. Brümmendorf TH, Kaul S, Schuhmacher J, Baum RP, Klivenyi G, Matys R, Gückel B, Eichler A, Beldermann F, Bastert G: Immunszintigraphie xenotransplantierter Mammakarzinome mit Tc-99m markierten monoklonalen Anti-Muzinantikörpern BM-7 und 12H12. Nucl Med 34 (1995) 197-202 92. Steinsträßer A, Oberhausen E and the European Multicenter Trial Group: Granulocyte Labelling Kit BW 250/183. Nucl Med 35 (1996) 1-11 93. Brümmendorf TH, Kaul S, Baum RP, Salgado L, Schuhmacher J, Vieira MR, Klivenyi G, Matys R, Fonseca AT, Bastert G: Immunoscintigraphic imaging of breast cancer with Tc99m-labelled anti-mucin antibody 12H12: Experimental and first clinical results. Tumor Targeting 2 (1996) 29-36 94. Eisenhut M, Lehmann WD, Becker W, Behr T, Elser H, Steinsträsser A, Baum RP, Valerius T, Repp R, Deo Y: Bifunctional NHS-BAT ester for antibody conjugation and stable 99m-Tc labeling: Conjugation chemistry, immunoreactivity and kit formulation. J Nucl Med 37 (1996) 362-370 95. Adamietz IA, Baum RP, Schemman F, Niesen A, Knecht R, Saran F, Tieku S, Boniface GR, Hör G, Böttcher HD: Improvement of radiation treatment planning in patients with squamous cell cancers of the head and neck region by immuno-SPECT. J Nucl Med 37 (1996) 1942-1946 96. Oltrogge JB, Donnerstag B, Baum RP, Noujaim AA, Träger L: Generation of human monoclonal anti-idiotypic antibodies with specificity to the murine monoclonal anti-CA 125 antibody B43.13. Int J Biol Markers 11 (1996) 211-215 97. Krause BJ, Baum RP, Staib-Sebler E, Lorenz M, Encke A: Human monoclonal antibody Tc-99m-88BV59: Detection of colorectal cancer, recurrent of metastatic disease and immunogenicity assessment. Eur J Nucl Med 24 (1997) 72-75 98. Driever PH, Göhlich-Ratmann G, König R, Wedekind C, Kieslich M, Schmidt H, Baum RP, Heller K, Böhles HJ: Congenital microgastria and associated malformations. Eur J Pediatr 155 (1997) Originalni radovi u časopisima R. P. Baum (1985-2013) 99. Adams S, Baum RP, Adams Martin, Wenisch HJC, Schumm-Draeger PM, Encke A, Usadel KH, Hör G: Zur klinischen Wertigkeit der Somatostatinrezeptorszintigraphie. Med Klin 92 (1997) 138 - 143 100. Adams S, Baum RP, Adams M, Wenisch HJC, Schumm-Draeger PM, Encke A, Usadel KH, Hör G: Untersuchungen zur prä- und intraoperativen Lokalisation von neuroendokrinen Tumoren. Acta Medica Austriaca 24 (1997) 81-86 101. Oltrogge JB, Baum RP, Lema KN, Donnerstag B, Hör G: How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assays. Int J Biol Markers 12 (1997) 15-17 102. Hör G, Adams S, Baum RP, Hertel A, Adamietz I, Böttcher HD, Kollath J: Impact of SPECT and PET in Diagnostic Oncology. Diagn Oncol 4 (1997) 297-321 103. Hertel A, Weppner M, Baas H, Schreiner M, Maul FD, Baum RP, Fischer PA, Hör G: Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy. Nucl Med Commun 18 (1997) 811-822 104. Hesslewood SR, Keeling DH and the Radiopharmacy Committee of the European Association of Nuclear Medicine (Baum RP et al, Germany): Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med 24 (1997) 1179-1182 105. Wu J, Wu H, He G, Baum RP: Priliminary clinical application of Radioimmunoimaging in breast carcinoma using Tc-99m labelled anti-CA 15-3 monoclonal antibody MACA1. Chin J Nucl Med 17 (1997) 219-220 106. Madiyalakan R, Yang R, Schultes BC, Baum RP, Noujaim AA: OVAREX MAb-B43.13: IFN-gamma could improve the ovarian tumor cell sensitivity to CA 125-specific allogenic cytotoxic T cells. Hybridoma 16 (1997) 41-45 107. McQuarrie SA, Baum RP, Niesen A, Madiyalakan R, Korz W, Sykes TR, Sykes CJ, Hör G, McEwan AJB, Noujaim AA: Pharmacokinetics and radiation dosimetry of Tc-99m labelled monoclonal antibody B43.13 in ovarian cancer patients. Nucl Med Commun 18 (1997) 878-886 108. Oliva JP, Osorio M, Pimentel G, Borron M, Dopico R, Ortiz R, Velazco M, Ramos M, Collazo A, Collazo M, Baum RP: Detection de una metastasis cerebral desconocida empleando la radioimmunocetelleografia con el anticuerpo monoclonal IOR-EGF-R3- Tc99m. Rev Esp Med Nucl 16 (1997) 321-323 109. Serafini AN, Klein JL, Wolff BG, Baum RP, Chetanneau A, Pecking A, Fischman A, Hoover HC jr, Wynant GE, Subramanian R, Goroff DK, Hanna jr MG: Radioimmunoscintigraphy of recurrent, metastatic or occultcolorectal cancer with Tc-99m labeled totally human monoclonal antibody 88BV59H21 - 2V67-66 (88BV59, Onco-SPECT/CR-Tc): Results of pivotal, phase II multicenter studies. J Clin Oncol 16 (1998) 1777-1787 110. Rinne D, Baum RP, Hör G, Kaufmann R: Primary staging and follow-up of high-risk melanoma patients by whole-body F-18-FDG positron-emission-tomography (PET): Results of a prospective study in 100 patients. Cancer 82 (1998) 1664-1671 111. Baum RP, Brümmendorf TH: Radioimmunolocalization of primary and metastatic breast cancer. QJ Nucl Med 42 (1998) 33-42 112. Baum RP: Diagnostik des Mammakarzinoms: Positronen-Emissions-Tomographie. Frauenheilkunde plus 3 (1998) 142-145 Originalni radovi u časopisima R. P. Baum (1985-2013) 113. Adams S, Baum RP, Rink T, Schumm-Draeger PM, Usadel KH, Hör G: Limited value of F-18-FDG-PET for imaging of neuroendocrine tumors. Eur J Nucl Med 25 (1998) 79-83 114. Hör G, Kranert WT, Maul FD, Schröder O, Karimian-Tatriz A, Geb O, Baum RP, Scherer UW: Gated metabolic positron emission tomography (GAPET) of myocardium: F-18-FDGPET to optimize recognition of myocardial hibernation. Nucl Med Commun 19 (1998) 535545 115. Adams S, Baum RP, Hertel A, Wenisch HJC, Staib-Sebler E, Herrmann G, Encke A, Hör G: Intraoperative Gamma Probe Detection of Neuroendocrine Tumors. J Nucl Med 39 (1998)1155-1160 116. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hör G: Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen. Nucl Med Commun 19 (1998) 641-647 117. Hör G, Kranert WT, Maul FD, Schröder O, Karimian-Tatriz A, Geb O, Baum RP, Scherer UW: Gated metabolic positron emission tomography (GAPET) of the myocardium: F-18FDG-PET to optimize recognition of myocardial hibernation. Nucl Med Commun 19 (1998) 535-545 118. Wolff BG, Bolton J, Baum RP, Chetanneau, Peking A, Serafini AN, Fischman A, Klein JL, Wynant GE, Subramanian R, Goroff DK, Hanna MG and the PerImmune Multicenter Study Group: Radioimmunoscintigraphie of recurrent, metastatic or occult colorectal cancer with Tc-99m- 88BV59H21-2V67-66 (Onco-SPECT/CR-Tc), a totally human monoclonal antibody: Patient management benefit from a Phase III Multicenter Study. Dis Colon Rectum 41 (1998) 953-962 119. Adams S, Baum RP, Stuckensen T, Bitter K, Hör G: Prospective comparison of F-18FDG-PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25 (1998) 1255-1260 120. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hör G: Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 25 (1998) 1277-1283 121. Oliva JP, Pimentel G, Peralta R, Borron M, Ortiz R, Gutierrez J, Guerra J, Quesada W, Dopico R, Casanova F, Baum RP: Radioimmunocentelleografia del cancer colorectal empleando el anticuerpo monoclonal BW 431/26 anti-CEA. Resultados finales. Rev Esp Med Nuclear 17 (1998) 2-8 122. Schröder O, Trojan J, Zeuze, S, Baum RP: Eingeschränkte Wertigkeit der Fluor-18-FDGPET in der Differentialdiagnostik fokaler Leberläsionen bei Patienten mit chronischer Hepatitis C. Nuklearmedizin 37 (1998) 279-285 123. Schultes B, Baum RP, Niesen A, Noujaim AA, Madiyalakan R: Anti-idiotype induction therapy: anti-CA 125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother 46 (1998): 201-212 124. Weber T, Hanisch E, Baum RP, Seufert RM: Late results of heterotopic autotransplantation of splenic tissue and the greater omentum. World J Surg 22 (8) (1998) 883-889 125. McQuarrie SA, Riauka T, Baum RP, Sykes TR, Noujaim AA, Boni MacLean GD, McEwan AJ: The effects of circulating antigen on the pharmacokinetics of radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients. J Pharm Pharm Sci 1 (3), (1998) 115-125 Originalni radovi u časopisima R. P. Baum (1985-2013) 126. Schröder O, Hör G, Hertel A, Baum RP: Combined hyperinsulinsulinemic glucose clamp and oral acipimox for optimizing metabolic conditions during F-18 fluorodeoxyglucose gated PET cardiac imaging: comparative results. Nucl Med Commun 19 (1998) 867-874 127. Rahn AN, Baum RP, Adamietz IA, Adams S, Sengupta S, Mose S, Bormeth SB, Hör G, Böttcher HD: Value of 18F fluorodeoxyglucose positron emission tomography in radiotherapy planning of head-neck tumors. Strahlenther Onkol 174 (1998) 358-364 128. Mruck S, Baum RP, Rinne D, Hör G: Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: Validation by whole body FDGPET and conventional diagnostics. Anticancer Research 19 (1999) 2685-2690 129. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S: Fluorine18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J of Gastroenterol 94 (1999) 3314-3319 130. Lacic M, Bokulic T, Lukac J, Kovacic K, Baum RP, Kusic Z: Bone marrow scintigraphy for the detection of skeletal metatases in patients with breast cancer. Nucl Med Commun 20 (1999) 135-143 131. Kaufmann R, Werner R, Rinne D, Adams S, Baum RP: Combined detection of muscle involvement and cancer screening in dermatomyositis by positron-emission tomography. J Am Acad Dermatol (1999) 132. Lacic M, Bokulic T, Lukac J, Kovacic K, Baum RP, Kusic Z: Immunoscintigraphy with Tc99m-labelled monoclonal anti-CEA BW431/26 antibodies in patients with suspected recurrent and metastastic colorectal carcinom: Two-year follow-up. Nucl Med Commun 20 (1999) 859-865 133. Young H, Baum RP, Cremerius U, Herholz K, Lammertsma A, Hoekstra O, Pruium J, Price P: Measurement of clinical and sub-clinical tumour response using F-18fluorodeoxyglucose and positron emission tomography: Review 1999 EORTC Recommendations. Eur J Cancer 35 (1999) 1773-1782 134. Fuchs J, Gratz KF, Habild G, Gielow P, Schweinitz D, Baum RP: Immunoscintigraphy of xenotransplanted hepatoblastoma with iodine 131-labeled anti-alpha-fetoprotein monoclonal antibody. J Pediatr Surg 34 (1999) 1378-1384 135. Weidmann E, Baican B, Hertel A, Baum RP; Chow KU, Knupp B, Adams S, Hör G, Hoelzer D, Mitrou PS: Positron-Emission-Tomography (PET) for staging and evaluation of Response to treatment in patients with Hodglin´s Disease. Leukemia and Lymphoma 34 (1999) 545-551 136. Oliva J, Pimentel G,.Peralta R, Borron M, Ortiz R, Gutierrez J, Guerra J, Quesado W, Dopico R. Casanova F. Baum RP: Radioimmunoscintigraphy of colorectal cancer using the anti-CEA monoclonal antibody BW 431/26. Final results. Rev Esp Med Nucl 18 (1999) 5-15 137. Baum RP: At the Crossroads: From cancer imaging and therapy using radiolabeld monoclonal antibodies to metabolic tumour imaging with positron emission tomography (PET). Int I Nucl Med 14 (1999) 51-66 138. Wu H, Wu J, Baum RP: Preliminary clinical application of radioimmunoimaging of breast cancer using Tc-99m-labeled anti-mucin monoclonal antibody. Chin J Nucl Med 20 (2000) 75-77 139. Adams S, Baum RP: Intraoperative use of gamma-detecting probes to localize neuroendorine tumors. Q J Nucl Med 44 (2000) 59-67 Originalni radovi u časopisima R. P. Baum (1985-2013) 140. Stuckensen T, Kovacs AF, Adams S, Baum RP: Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Cranio-Maxillofacial Surgery 28 (2000) 319-324 141. Przetak C, Baum RP, Niesen A, Slomka P, Pröschild A, Leonhardi J: Anatometabolische Bildfusion von PET, CT und MRT. Nuklearmediziner 23 (2000) 355-367 142. Baum RP, Rinne D Kaufmann R: Klinischer Stellenwert der Positronenemissionstomographie im Primärstaging und in der Nachsorge des malignen Melanoms. Nuklearmediziner 23 (2000) 377-390 143. Griesinger F, Baum RP: Klinische Notwendigkeit und Bedeutung der Früherfassung der Therapie-Response beim Bronchialkarzinom. Nuklearmediziner 24 (2001) 25-29 144. Adams S, Baum RP, Hör G: Wertigkeit der F-18-FDG-PET bei neuroendokrinen Tumoren. Nuklearmediziner 24 (2001) 39-46 145. Adams S, Baum RP, Knecht R, Hör G: Staging und Rezidivdiagnostik von Tumoren im Kopf-Hals-Bereich. Nuklearmediziner 24 (2001) 47-54 146. Przetak C, Baum RP, Slomka PJ: Image fusion raises clinical value of PET. Diagnostic Imaging Europe 17, No. 5 (2001) 10-15 147. Niesen A, Przetak C, Baum RP: Nuklearmedizinische Diagnostik und Therapie bei pneumologischen Erkrankungen. Ärztebl. Thüring. 12 (2001) 6, 321-324 148. Noujaim AA, Schultes BC, Baum RP, Madiyalakan R : Induction of CA 125-specific B- and T-cell responses in patients injected with MAb-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 16(3) (2001): 187-203 149. Baum RP, Bonnet RB, Presselt N, Leonhardi J: Positronen-Emissions-Tomographie (PET) mit F-18-FDG in der Diagnostik des Bronchialkarzinoms und zur Dignitätsklärung von pulmonalen Raumforderungen. Nuklearmediziner (2001) 9-23 150. Baum RP, Przetak Ch: Evaluation of therapy response in breast an ovarian Cancer patients by positron emission tomography (PET). Q J Nucl Med 45 (2001) 257-268 151. Oliva JP, Pimentel G, Borron M, Peralta R, Ortiz R, Oliver B, Diaz B, Sanchez I, Vazquez AM, Baum RP: Pilot study with the monoclonal antibody IOR-C5 as a potential agent for radioimmunoscintigraphy in colorectal cancer. [Ensayo piloto con el anticuerop monoclonal ior-C4 como agente potencial de la immunocentelleografia del cancer colorectal.] Rev Esp Med Nucl 24, 4 (2001) 282-288 152. Hör G, Baum RP: Impact of (Satellite-) PET on Cardiology and Cardiac Surgery. In: Impact of Clinical PET and PET Research Perspectives - Positron-Emission-Tomography. Proceedings of the 20. Seminar of the European School of Medicine, Bratislava 2002 153. Timm S, Sailer M, Baum RP, Debus ES, Thiede A: Die Wertigkeit der Positronenemissionstomographie (PET) in der Nachsorge des Rektumkarzinoms. Coloproctology 24 (2002) 197-202 154. Przetak Ch, Baum RP: Positronen-Emissions-Tomographie (PET) in der Diagnostik von Hirntumoren. Dt. Hirntumorhilfe - BrainStorm 1/2002, 11 18 155. Wu J, Baum RP: The F-FDG uptake in Non Small Cell Lung Carcinoma correlates with the DNA-grading of malignancy. Chin J Nucl Med 22 (2) (2002) 116-117 Originalni radovi u časopisima R. P. Baum (1985-2013) 156. König T, Baum RP, Radtke M, Franke D: HAMA-ELISA medac: A new assay for the quantification of human anti-mouse antibodies. Clin Lab 3+4 (2002) 207-210 157. Möbus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC, Nicodemus CF: Immune responses to murine monoclonal antibody – B43.14 correlate with prolonged survival of woman with recurrent ovarian cancer. Am J Obstet Gynecol 189 (2003) 28-36 158. Slomka PJ, Damini D, Przetak C, Aladl UE, Baum RP: Automated 3-dimensional registration of stand-alone F18-FDG whole-body PET with CT. J Nucl Med 44 (2003) 1156-1167 159. Schmücking M, Baum RP, Griesinger F, Presselt N, Bonnet R, Przetak C, Niesen A, Leonhardi J, Lopatta EC, Herse B, Wendt TG: Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res 162 (2003) 195-202 160. Mantaka P, Baum RP, Hertel A, Adams S, Niesen A, Sengupta S, Hör G: PET with 2-[f18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patient´s diagnostic and therapeutic management. Cancer Biother Radiopharm 18 (2003) 47-58 161. Schmücking M, Baum RP, Griesinger F, Presselt N, Bonnet R, Przetak C, Niesen A, Leonhardi J, Lopatta EC, Herse B, Wendt TG: Molecular whole-body cancer staging using positron-emission-tomography: Consequences for therapeutic management and metabolic radiation treatment planning. Recent Results in Cancer Research 162 (2003) 195-202 162. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L. Moncayo R, Mortelmans L, Reske SN: FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30 (2003) BP115-BP124 163. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L. Moncayo R, Mortelmans L, Reske SN: Breast scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30 (2003) BP 107-BP114 164. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Mortelsman L, Reske SN: Bone scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30 (2003) BP99-BP106 165. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli 67 L, Moncayo R, Mortelsman L, Reske SN: Ga scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30 (2003) BP125-BP131 166. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli 131 123 L, Moncayo R, Mortelsman L, Reske SN: I/ I_metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30 (2003) BP 132-139 167. Bombardieri E, Aktolun C, Baum RP, Bischof-Delaloye A, Buscombe J, Chatal JF, Maffiolo L, Moncayo R, Mortelsmans L, Reske SN: 111In-pentetreotide scintigraphy: procedure guidelines for tumor imaging. Eur J Nucl Med Mol Imaging 30 (2003) BP140-147 168. Oliva JP, Cruz T, Pimentel G, Quesada W, Ortiz R, Abreu M, Sanchez I, Diaz N, Baum RP: Radioimmunolocalization of head and neck tumors with a new monoclonal antibody to EGF receptor. Preliminary results. Rev Esp Med Nucl 23 (4) (2004) 273-278 169. Baum RP: Oregovomab – A viewpoint. Am J Cancer 2 (2) (2003) 125-133 Originalni radovi u časopisima R. P. Baum (1985-2013) 170. Baum RP, Hellwig D, Mezzetti M: Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. QJ Nucl Med Imaging 48 (2004) 119-142 171. Baum RP, Hofmann M: Nuklearmedizinische Diagnostik neuroendokriner Tumoren. Onkologe 10 (2004) 598-610 172. Baum RP, Söldner J, Schmücking M, Niesen A: Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren. Onkologe 10 (2004) 1098-1110 173. Hamm KD, Surber G, Schmücking M, Wurm RE, Aschenbach R, Kleinert G, Niesen A, Baum RP: Sterotactic radiation treatment planning and follow-up studies involving fused multimodality imaging. J Neurosurg (Suppl 3) 101 (2004) 326-333 174. Oliva JP, Cruz T, Pimentel G, Quesada W, Ortiz R, Abreu M, Sanchez I, Diaz N, Baum RP: Radioimmunolocalization of head and neck tumors with a new monoclonal antibody to EGF receptor. Preliminary results. Rev Esp Med Nucl 23 (4) (2004) 273-278 175. Baum RP, Hellwig D, Mezzetti M: Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Imaging 48 (2004) 119-142 176. Baum RP: Aktueller Stand der Positronenemissionstomographie (PET) bei onkologischen Fragestellungen – neue Radiopharmazeutika und neue Technik (PET/CT). Der Nuklearmedizinier 27 (2004) 217 – Gastherausgeber des Themenheftes 177. Oehler W, Baum RP: Aktueller Beitrag der PET und PET/CT zur Zielvolumenmodulation für die biologisch-medizinische Planung im Rahmen der intensitätsmodulierten Strahlentherapie (IMRT). Der Nuklearmedizinier 27 (2004) 324-329 178. Schmücking M, Baum RP, Bonnet R, Junker K, Müller KM: Korrelation histologischer und nuklearmedizinischer Befunde der Tumorregression in behandelten bösartigen Lungentumoren. Pathologe 26 (2005) 178-190 179. Oliva JP, Pimentel G, Velasco M, Martinez A, Ortiz R, Abreu M, Diaz N, Oliver B, Sanchez I, Valladares T, Baum RP: Radio-immunodetection of Colorectal Cancer using Tc-99m labeled Monoclonal Antibody ior-CEA1: Results of a Phase III Clinical Trial. W J Nucl Med 4 (2005) 150-158 180. Ruffini V, Calcagni ML, BaumRP: Imaging of Neuroendocrine Tumors. Semin Nucl Med 36 (2006) 228-247 181. Verheijen RH, Massuge LF, Benigno, BB et al.: Phase III trial of intraperitoneal therapy with Yttrium-90-labeled HMFG1 murine monocloncal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncology 24 (2006) 571-577 182. Piel M, Baumann A, Baum RP, Höhnemann S, Klette I, Wortmann R, Rösch F: Improved automated synthesis of [18-F] fluoroethylcholine as a radiotracer for prostate cancer imaging and first clinical results using PET/CT. – Bioorganic & Medicinal Chemistry 15 (2007) 3171-3175 183. Zhernosekov KP, Filosofov, DV, Baum RP, Aschoff P, Bihl h, Rabash A, Jahn, M, Jenne68 wein M, Rösch F: Processing of Generator-Produced Ga for Medical Application. J Nucl Med 48 (2007) 1741-1748 184. Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP: Results of Individual Patient 177 177 Dosimetry iin Peptide Receptor Radionuclide Therapy with Lu DOTA-TATE and Lu DOTA-NOC. Cancer Biotherapy & Radiopharmaceuticals 22 (2007) 406 -416 Originalni radovi u časopisima R. P. Baum (1985-2013) 185. Antunes P, Ginj M, Zlang H, Wasser B, Baum RP, Reubi JC, Maecke H: Are radiogalliumlabelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34 (2007) 982-993 186. Gulec SA, Baum RP: Radio-Guided Surgery in Neuroendocrine Tumors. J Surg Oncol 96 (2007) 309-315 187. Prasad V, Fetscher S, Baum RP: Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine´s View. J Pharm Pharmaceut Sci 10 (2007) 321-337 188. Gottschaldt M, Koth D, Müller D, Klette I, Rau S, Görls H, Schäfer B, Baum RP, Yano S: Synthesis and structure of novel sugar-substituted bipyridine complexes of rhenium and 99m-technetium. Chemistry. 2007;13 (36):10273-80. 189. Baum RP, Prasad, V, Hommann M, Hörsch D: Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res. 170 (2008) 225-42. 190. Rimpler A, Barth I, Baum RP, Senftleben S, Geworski L: Beta radiation exposure of staff 90 during and after therapies with with Y-labelled substances. Radiation Protection Dosimetry 131 (1) (2008) 73-79 191. Baum RP. Prasad V: Stellenwert der PET bzw. PET/CT mit F18-FDG beim kleinzelligen Lungenkarzinom. Onkologe 14 (2008) 774-782 192. Rössler A, Niesen A, Baum RP: Parkinson-Krankheit und Parkinson-Syndrom. Ärzteblatt Thüringen19 (5) (2008) 273-277 193. Hellwig, D, Baum RP, Kirsch CM: FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer – A systematic review. Nuklearmedizin 48 (2009) 59-69 194. Slomka P, Baum RP: Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol Imaging 36 (1) (2009) S44-55. Review 195. Gottschaldt M, Bohlender C, Müller D, Klette I, Baum RP, Yano S, Schubert SU: Rhenium and 99m-technetium complexes of monosaccharide based tripodal triamines as potential radio imaging agents, Dalton Trans 26 (2009), 5148-5154 196. Baum RP, Prasad V, Hörsch D: Molekulare Bildgebung neuroendokriner Tumoren mit 68 Ga-markierten Peptiden (Somatostatinrezeptor-PET/CT). Nuklearmediziner 32 (2009) 115-130 197. Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP: Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatov tumor. Wordl J Gastroenterol 15 (46) (2009) 5867-5870 198. Gottschaldt M, Bohlender C, Pospiech A, Görls H, Walther M, Müller D, Klette I, Baum III III RP, Schubert US: In and Ga Complexes of Sugar Substituted Tripodal Trisalicylidene Imines: The First 68Ga Labelled Sugar Derivative. Eur J Inorg Chem 28 (2009) 4298– 4307 199. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP: Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37 (1) (2010) 67-77 200. Prasad V, Baum RP: Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions.Q J Nucl Med Imaging 54 (2010) 61-67 Originalni radovi u časopisima R. P. Baum (1985-2013) 201. Baum RP, Świętaszczyk C, Prasad V: FDG-PET/CT in Lung Cancer: an Update. Front Radiat Ther Oncol 42 (2010) 15-45 202. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37 (2010) 181-200 203. Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37 (1) (2010) 181-200 204. Baum RP: Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg Am Tolmachev V, Feldwisch J: Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer 111 68 Patients using Synthetic In- or Ga-Labeled Affibody Molecules. J Nucl Med 51 (2010) 892-897 205. Riemann B, Krämer JA, Schmid JA, Dralle H, Dietlein M, Schicha H, Sauerland C, Frankewitsch T, Schober O for the MSDS study group: Risk stratification of patients with locally aggressive differentiated thyroid cancer – Results of the MSDS trial. Nuklearmedizin 49 (2010) 79-84 206. Bombardieri E, Ambrosini V. Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A: Eur J Nucl Med Mol Imaging 37 (2010) 1441-1448 207. Fellner M, Baum RP, Kubiček V, Hermann P, Lukeš I, Prasad V, Rösch F: PET/CT imag68 ing of osteoblastic bones metastases with Ga-biphosphonates: first human study. Eur J Nucl Med Mol Imaging 37 (2010) 834 208. Schmidt M, Baum RP, Simon T, Howman-Giles R: Therapeutic nuclear medicine in pediatric malignancy. Q J Nucl Med Mol Imaging 54 (4) (2010) 411-428 209. Erlic Z, Ploeckinger U, Cascon A, Hoffmann MM, von Duecker L, Winter A, Kammel G, Bacher J, Sullivan M, Isermann B, Fischer L, Raffel A, Knoefel WT, Schott M, Baumann T, Schaefer O, Keck T, Baum RP, Milos I, Muresan M, Peczkowska M, Januszewicz A, Cupisti K, Tönjes A, Fasshauer M, Langrehr J, von Wussow P, Agaimy A, Schlimok G, Lamberts R, Wiech T, Schmid KW, Weber A, Nunez M, Robledo M, Eng C, Neumann HPH, and for the VHL-ICT Consortium and the German NET Registry: Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. Endocr. Relat. Cancer 17 (2010) 875 – 883 210. Oh S, Prasad V, Lee DS, Baum RP: Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging. 2011;2011:524130. doi: 10.1155/2011/524130. Epub 2011 Nov 9. 211. Rösch F, Baum RP: Generator-based PET radiopharmaceuticals for molecular imaging if tumors: in the way to THERANOSTICS. Dalton Trans (2011) DOI: 10.1039/C0DT01504K 212. Baum RP, Kluge A, Gildehaus FJ, Bronzel M, Schmidt K, Schuchardt C, Senftleben S, Samnick S: Systemic Endoradiotherapy with Carrier-Added 4-[131I] Iodo-L-Phenylalanine: Clinical Proof-of-Principle in Refractory Glioma. Nucl Med Mol Imaging 45 (2011) 299-307 Originalni radovi u časopisima R. P. Baum (1985-2013) 213. Pesek M, Baum RP, Sedlackova E, Slipkova D, Krakorova G: Radiopeptidova terapie metastazujiciho karcinoidu – prvni zkusenosti. Stud Pneumol Phthiseol 71 (2011) 88-92 B 214. Bushnell DL, Baum RP: Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1) (2011) 53-62 215. Hommann M, Kaemmerer D, Daffner W, Prasad V, Baum RP, Petrovitch A, Sauerbrey A, Katenkamp K, Kaufmann R, Settmacher U: Nested stromal epithelial tumor of the liver-liver transplantation and follow-up. J Gastrointest Cancer 42(4) (2011) 292-5. 216. Mueller D, Klette I, Kalb F, Baum RP. Synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine based on a cartridge purification method. Nucl Med Biol. 38(5) (2011) 653-8. 217. Hörsch D, Grabowski P, Schneider CP, Petrovitch A, Kaemmerer D, Hommann M, Baum RP: Current treatment options for neuroendocrine tumors. Drugs Today 47(10) (2011) 773-86 218. Kolenc-Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, Baum RP, Reubi JC, Maecke HR: Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem 54(8) (2011) 2602-9 219. Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP: Comparison of sequenzial planar Lu-177-DOTA-TATE dosimetry scans with Ga-68-DOTATATE PET/CT images in patients with metastasized neuroendokrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 38 (2012) 501-511 220. Baum RP, Kulkarni HR, Carreras C: Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms. Semin Nucl Med 42 (2012) 190-207 221. Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Baum RP, Prasad V, Hommann M: Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int H Clin Exp Pathol 5(3) (2012) 187-194 222. Rufini V, Baum RP, Castaldi P, Treglia G, De Gaetano AM, Carreras C, Kaemmerer D, Hommann M, Hörsch D, Bonomo L, Giordano A: Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 37(6) (2012) 1004-20 223. Swiętaszczyk C, Prasad V, Baum RP: Intense 18F-fluoride accumulation in liver metastases from a neuroendocrine tumor after peptide receptor radionuclide therapy. Clin Nucl Med. 37(4) (2012) 82-3 224. Salavati A, Prasad V, Schneider CP, Herbst R, Baum RP: Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med 26(4) (2012) 365-9 225. Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, Plöckinger U, Papotti M, Salazar R, Pascher A; Barcelona Consensus Conference participants: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 95(2) (2012) 88-97 226. Hörsch D, Sayeg Y, Bonnet R, Kaemmerer D, Presselt N, Baum RP: Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system. Pneumologie 66(1) (2012) 44-8 Originalni radovi u časopisima R. P. Baum (1985-2013) 227. Kaemmerer D, Prasad V, Daffner W, Haugvik SP, Senftleben S, Baum RP, Hommann M: Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. Clin Nucl Med 37(2) (2012) 142-7 228. Baum RP, Kulkarni HP: Theranostics: From Molecular Imaging using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy – The Bad Berka Experience. Theranostics 2 (5) (2012) 437-447 229. Schultz MK, Mueller D, Baum RP, Leonard Watkins G, Breeman WA: A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot.76 (2013):46-54 230. Schmidt MC, Uhrhan K, Markiefka B, Hasselbring L, Schlaak M, Cremer B, Kunze S, Baum RP, Dietlein M: (68)Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capecitabine in two patients with Merkel Cell Carcinoma. Int J Clin Exp Med 5(4) (2012) 363-6 231. Hörsch D, Bert T, Schrader J, Hommann M, Kaemmerer D, Petrovitch A, Zaknun J, Baum RP: Pancreatic neuroendocrine neoplasms. Minerva Gastroenterol Dietol 58 (4) (2012) 401-26. Review. 232. Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D: Vandetanib therapy in medullary thyroid cancer. Drugs Today (Barc) 48(11) (2012) 723-33. Review. 233. Feyen O, Coy JF, Prasad V, Schierl R, Saenger J, Baum RP: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol 8(10) (2012) 1349-59 234. Knapp FF Jr, Baum RP: Radionuclide generators - a new renaissance in the development of technologies to provide diagnostic and therapeutic radioisotopes for clinical applications. Curr Radiopharm. 5(3) (2012) 175-7 235. Mueller D, Klette I, Baum RP, Gottschaldt M, Schultz MK, Breeman WA: Simplified NaCl Based (68)Ga Concentration and Labeling Procedure for Rapid Synthesis of (68)Ga Radiopharmaceuticals in High Radiochemical Purity. Bioconjug Chem Bioconjug Chem 23(8) (2012) 1712-7 236. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, O'Dorisio MS, O'Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40 (5) (2013 )800-16 237. Kulkarni HR, Prasad V, Schuchardt C, Baum RP: Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose? Recent Results Cancer Res 194 (2013) 561-6 238. Kulkarni HR, Schuchardt C, Baum RP: Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient. Recent Results Cancer Res 194 (2013) 551-9 239. Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP: The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.Recent Results Cancer Res 194 (2013) 519-36 240. Todorović-Tirnanić M, Kaemmerer D, Prasad V, Hommann M, Baum RP: Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- Originalni radovi u časopisima R. P. Baum (1985-2013) and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Recent Results Cancer Res 194 (2013) 487-96 241. Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Krause BJ, Schümichen C, Bengel FM, Knapp WH, Bartenstein P, Biersack HJ, Plöckinger U, Schwartz-Fuchs S, Baum RP: Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent Results Cancer Res 194 (2013) 457-65 242. Carreras C, Kulkarni HR, Baum RP: Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors. Recent Results Cancer Res194 (2013) 379-84 243. Kulkarni HR, Prasad V, Kaemmerer D, Hommann M, Baum RP: High uptake of (68)GaDOTATOC in spleen as compared to splenosis: measurement by PET/CT. Recent Results Cancer Res 194 (2013) 373-8 244. Mueller D, Klette I, Baum RP: Purification and labeling strategies for (68)Ga from (68)Ge/ (68)Ga generator eluate. Recent Results Cancer Res 194 (2013) 77-87 Originalni radovi u časopisima R. P. Baum (1985-2013) 245. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papthanasiou ND, Pepe G, Oyen W, De Dristoforo C, Chiti A: Procedure guidelines for PET/CT tumour imaging 68 68 68 68 with Ga-DOTA-conjugated peptides: Ga-DOTA-TOC, Ga-DOTA-NOC, Ga-DOTATATE. Eur J Nucl Med Mol Imaging DOI 10.1007/s00259-010-1512-3 246. Kadir T, Platsch G, Baum RP, Declerck J: Labelling of Vertebrae in NaF-PET. Transactions on Medical Imaging (accepted)
